Stelios Papadopoulos Sells 36,508 Shares of Exelixis, Inc. (NASDAQ:EXEL) Stock

Exelixis, Inc. (NASDAQ:EXEL) Director Stelios Papadopoulos sold 36,508 shares of the stock in a transaction that occurred on Thursday, May 15th. The shares were sold at an average price of $44.35, for a total transaction of $1,619,129.80. Following the sale, the director now directly owns 1,279,416 shares in the company, valued at $56,742,099.60. This trade represents a 2.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Exelixis Stock Down 1.9%

Shares of NASDAQ EXEL opened at $45.40 on Friday. Exelixis, Inc. has a twelve month low of $20.14 and a twelve month high of $48.85. The company’s fifty day moving average is $37.23 and its 200-day moving average is $35.82. The stock has a market cap of $12.51 billion, a price-to-earnings ratio of 25.65, a P/E/G ratio of 1.13 and a beta of 0.25.

Institutional Investors Weigh In On Exelixis

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its holdings in shares of Exelixis by 0.4% during the fourth quarter. Vanguard Group Inc. now owns 29,429,252 shares of the biotechnology company’s stock worth $979,994,000 after acquiring an additional 121,750 shares during the period. LSV Asset Management raised its holdings in shares of Exelixis by 0.8% during the fourth quarter. LSV Asset Management now owns 8,169,847 shares of the biotechnology company’s stock worth $272,056,000 after acquiring an additional 67,470 shares during the period. Fuller & Thaler Asset Management Inc. raised its holdings in shares of Exelixis by 2.2% during the first quarter. Fuller & Thaler Asset Management Inc. now owns 7,795,074 shares of the biotechnology company’s stock worth $287,794,000 after acquiring an additional 164,134 shares during the period. AQR Capital Management LLC raised its holdings in shares of Exelixis by 73.8% during the first quarter. AQR Capital Management LLC now owns 6,893,889 shares of the biotechnology company’s stock worth $250,869,000 after acquiring an additional 2,926,884 shares during the period. Finally, Invesco Ltd. raised its holdings in shares of Exelixis by 40.2% during the first quarter. Invesco Ltd. now owns 5,572,189 shares of the biotechnology company’s stock worth $205,725,000 after acquiring an additional 1,596,948 shares during the period. 85.27% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have issued reports on EXEL shares. Piper Sandler raised their price objective on shares of Exelixis from $37.00 to $38.00 and gave the company an “overweight” rating in a research note on Wednesday, February 12th. Wells Fargo & Company reaffirmed a “market outperform” rating on shares of Exelixis in a research note on Thursday, April 17th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $40.00 price objective on shares of Exelixis in a research note on Wednesday. UBS Group reaffirmed an “underperform” rating on shares of Exelixis in a research note on Thursday, April 17th. Finally, StockNews.com cut shares of Exelixis from a “strong-buy” rating to a “buy” rating in a research note on Thursday. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $38.76.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.